LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

Kezdőlap・Részvénylista・Travere Therapeutics Inc

Travere Therapeutics Inc

Lezárt

51.97 6.17

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

51.71

Maximum

52.66

Fő mutatók
By Trading Economics
Bevétel	-15M -37M
Értékesítés	-2.5M 127M
Egy részvényre jutó nyereség	-0.4
Profit margin	-28.775
Munkavállalók	497
EBITDA	-11M -12M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+8.42% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. aug. 5.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	490M 4.3B
Előző nyitás	45.8
Előző zárás	51.97

Travere Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. jún. 13. 23:52 UTC

China's House Price Index YoY release on June 16, 2026, faces cautious market sentiment amid ongoing declines and geopolitical tensions.

2026. jún. 13. 23:51 UTC

Correlated Moves

Bitcoin has advanced since Friday, reflecting positive sentiment in the cryptocurrency market. The asset remains below its 20-day moving average and near its one-month range low.

2026. jún. 13. 23:41 UTC

U.S. Stocks Surge on SpaceX IPO and Optimism Over U.S.-Iran Peace Talks, While Traders Anticipate Fed's Interest Rate Decision Amid Inflation Concerns.

2026. jún. 13. 23:41 UTC

U.S. Stocks Surge on Peace Deal Optimism, Fed Expected to Hold Rates Amid Geopolitical Tensions and Key Economic Data Ahead.

2026. jún. 13. 23:41 UTC

U.S. Stocks Surge on Peace Deal Optimism and Global Mineral Economy Shift Ahead of Steady Fed Rate Decision.

2026. jún. 13. 23:41 UTC

U.S. Stocks Surge on SpaceX IPO and Peace Deal Hopes, While Investors Brace for Key Economic Data and Fed Rate Decision.

2026. jún. 13. 23:41 UTC

Philadelphia Fed Manufacturing Index Release on June 18, 2026, Anticipates Growth Amid Mixed Economic Sentiment and Inflation Concerns.

2026. jún. 13. 23:31 UTC

U.S. Industrial Production MoM data for May 2026 expected to rise by 0.2% amid cautious optimism following April's strong performance of 0.7%.

2026. jún. 13. 23:21 UTC

U.S. Retail Sales MoM Report on June 17 Expected to Show Modest 0.5% Increase Amid Geopolitical Tensions and Consumer Spending Optimism

2026. jún. 13. 23:21 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in May Amid Cautious Consumer Sentiment and Economic Resilience

2026. jún. 13. 23:21 UTC

Canada's New Housing Price Index set for June 17 release, with a forecasted slight decline amid ongoing affordability challenges and government announcements.

2026. jún. 13. 23:11 UTC

Market Anticipates U.S. Building Permits Data Release Amid Cautious Optimism and Economic Concerns on June 16, 2026.

2026. jún. 13. 23:02 UTC

India's RBI to release monetary policy meeting minutes amid lower-than-expected CPI inflation and rising food costs, influencing future interest rate decisions.

2026. jún. 13. 23:02 UTC

Upcoming U.S. Housing Starts Data Release on June 16, 2026 Expected to Reflect Economic Conditions Amid Government Initiatives and Rising Demand.

2026. jún. 13. 23:02 UTC

Investors Anticipate Further Increases in U.S. Export Prices Ahead of June 16 Release Amid Geopolitical Developments

2026. jún. 13. 23:02 UTC

U.S. Housing Starts Expected to Reach 1.44 Million Units in May Amid Mixed Trends and Policy Discussions Ahead of June 16 Release

2026. jún. 13. 23:02 UTC

U.S. Import Prices Report on June 16 Expected to Show 0.9% Increase Amid Geopolitical Optimism and Inflation Concerns

2026. jún. 13. 23:02 UTC

Market Anticipates 1.41 Million Building Permits in May 2026 Amidst Cautious Optimism for Housing Sector Recovery.

2026. jún. 13. 23:01 UTC

Macro News

DAX 30 Index rises in after-market trading amid optimism for a U.S.-Iran peace deal and President Trump's announcement on the Strait of Hormuz.

2026. jún. 13. 22:51 UTC

Japan's Year-on-Year Inflation Rate Release on June 18 Expected to Show Stability Amid Mixed Economic Signals and Global Influences.

2026. jún. 13. 22:51 UTC

Japan's Core Inflation Rate Expected to Hold at 1.4% Amid Cautious Market Sentiment and BOJ Policy Considerations

2026. jún. 13. 22:41 UTC

Market anticipates June 15 release of NY Empire State Manufacturing Index at 13.2, signaling cautious optimism amid inflation concerns and geopolitical developments.

2026. jún. 13. 22:41 UTC

Japan's Machinery Orders Expected to Rise 0.9% in April Amidst Mixed Economic Signals and Improving Investor Confidence

2026. jún. 13. 22:41 UTC

Japan's Exports Expected to Rise 0.162% YoY in June Amid Positive Economic Sentiment and Geopolitical Easing, Despite Competition from China

2026. jún. 13. 22:41 UTC

Mortgage Rates Set to Rise Amid Geopolitical Tensions and Economic Uncertainty, with Upcoming MBA Report Expected on June 17.

2026. jún. 13. 22:32 UTC

UK Consumer Confidence Index for June 2026 Forecasted at -23 Amid Ongoing Inflation and Economic Uncertainty

2026. jún. 13. 22:32 UTC

Canada's May 2026 Housing Starts Data Set for Release, Forecasted at 255K Units Amid Optimistic Market Sentiment and Government Initiatives.

2026. jún. 13. 22:32 UTC

Brazil's Central Bank to Provide Key Interest Rate Insights on June 15, Amidst Cautious Market Sentiment and Global Economic Influences.

2026. jún. 13. 22:32 UTC

Japan's trade deficit forecasted at -564.6 billion yen amid high import costs, but market optimism rises following easing U.S.-Iran tensions and strong Asian stock performance.

2026. jún. 13. 22:32 UTC

Brazil's Retail Sales Report on June 16 Expected to Show Resilience Amid Mixed Economic Signals

Társak összehasonlítása

Árváltozás

Travere Therapeutics Inc Előrejelzés

Célár

By TipRanks

8.42% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 56.42 USD 8.42%

Magas 67 USD

Alacsony 43 USD

12 Wall Street elemző 12 hónapos célárain alapulva a(z)Travere Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

12 ratings

Vétel

Tartás

Eladás

12 Wall Street elemző célárain alapulva a(z)Travere Therapeutics Inc termékhez az elmúlt 3 hónapban.

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.